EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories

Rodrigo Cánovas iD, Christopher J Fowler, Azadeh Feizpour, Vincent Dóre, Pierrick Bourgeat, Ziad S Saad, Gallen Triana-Baltzer, Hartmuth C Kolb, Manu Vandijck, Gwendlyn Kollmorgen, Clara Quijano-Rubio, Jurgen Fripp und 10 weitere

Alzheimer's & Dementia · 2026-02 · 22 (2)

DOI: 10.1002/alz.71145 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alzheimer's & Dementia, online erschienen am 09.02.2026. Verfasst von Rodrigo Cánovas und 21 weiteren Autor:innen. Beteiligte Einrichtung: The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia. Hauptthemen laut MEDLINE: tau Proteins, Positron-Emission Tomography, Amyloid beta-Peptides, Alzheimer Disease. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: AbbVie, Swedish Research Council, European Union's Horizon Europe research and innovation programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

INTRODUCTION With increased uptake in disease‐modifying treatments for amyloid beta (Aβ) removal, it is important to measure performance of highly sensitive plasma biomarkers to detect the presence of Aβ and tau in cognitively impaired populations. METHODS In this study, we investigated a large set of plasma biomarkers for their capability to predict Aβ and tau positron emission tomography (PET) and their association with increasing Aβ and tau burden. RESULTS From the biomarkers assessed, tau phosphorylated at threonine 217 (pTau217) showed the largest increases across the full range of Aβ and tau levels. Furthermore, pTau217/Aβ42 had the smallest proportion of participants in the intermediate zone (∼4%) to predict Aβ status using a 90/90% dual cut‐off for sensitivity and specificity, with < 20% of participants in the intermediate zone using the 95/95% dual cut‐off. DISCUSSION While the studied biomarkers proved their utility to predict Aβ and tau PET at their respective thresholds, each has separate quantified responses to Aβ and tau aggregation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

tau ProteinsPositron-Emission TomographyAmyloid beta-PeptidesAlzheimer DiseaseHumansBiomarkersDisease ProgressionFemaleMaleAgedPhosphorylationBrainAged, 80 and over

Stichwörter der Autor:innen

Alzheimer's disease continuumamyloid betaassociationplasma biomarkerpositron emission tomography imagingpredictiontau

Substanzen

tau ProteinsAmyloid beta-PeptidesBiomarkers

Autor:innen und Institutionen

  • The Australian e-Health Research Centre, CSIRO, Melbourne, Victoria, Australia.
  • The Florey Institute of Neuroscience and Mental Health, the University of Melbourne, Parkville, Victoria, Australia.
  • Department of Molecular Imaging & Therapy, Austin Health, Melbourne, Victoria, Australia.
  • The Australian e-Health Research Centre, CSIRO, Brisbane, Queensland, Australia.
  • Precision Measures, Johnson & Johnson, San Diego, California, USA.
  • Fujirebio Europe N.V., Gent, Belgium.

ORCID-Profile: Rodrigo Cánovas

Förderung

  • AbbVie
  • Swedish Research Council
  • European Union's Horizon Europe research and innovation programme
  • Swedish State Support for Clinical Research
  • AD Strategic Fund
  • NEuroBioStand
  • Familjen Beiglers Stiftelse
  • Stiftelsen för Gamla Tjänarinnor

Zitieren

APA

Cánovas, R., Fowler, C. J., Feizpour, A., Dóre, V., Bourgeat, P., Saad, Z. S., Triana-Baltzer, G., Kolb, H. C., Vandijck, M., Kollmorgen, G., Quijano-Rubio, C., Fripp, J., Laws, S., Bannon, A. W., Blennow, K., Zetterberg, H., Rainey-Smith, S., Mathotaarachchi, S., Rowe, C. C., …, & AIBL Research Group (2026). Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories. Alzheimer's & Dementia, 22(2). https://doi.org/10.1002/alz.71145

Vancouver

Cánovas R, Fowler CJ, Feizpour A, Dóre V, Bourgeat P, Saad ZS, et al. Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories. Alzheimer's & Dementia. 2026;22(2). doi:10.1002/alz.71145

BibTeX
@article{Cnovas2026,
  author = {Cánovas, Rodrigo and Fowler, Christopher J and Feizpour, Azadeh and Dóre, Vincent and Bourgeat, Pierrick and Saad, Ziad S and Triana-Baltzer, Gallen and Kolb, Hartmuth C and Vandijck, Manu and Kollmorgen, Gwendlyn and Quijano-Rubio, Clara and Fripp, Jurgen and Laws, Simon and Bannon, Anthony W and Blennow, Kaj and Zetterberg, Henrik and Rainey-Smith, Stephanie and Mathotaarachchi, Sulantha and Rowe, Christopher C and Masters, Colin L and Doecke, James D and AIBL Research Group, AIBL Research Group},
  title = {Plasma biomarker progression across the Alzheimer's disease amyloid beta and tau positron emission tomography trajectories},
  journal = {Alzheimer's & Dementia},
  year = {2026},
  volume = {22},
  number = {2},
  doi = {10.1002/alz.71145}
}
Kostenlos starten →